{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:23:59Z","timestamp":1791509039931,"version":"4.3.4"},"reference-count":55,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010688","name":"Horizon 2020 European Innovation Council Fast Track to Innovation","doi-asserted-by":"publisher","award":["755021"],"award-info":[{"award-number":["755021"]}],"id":[{"id":"10.13039\/100010688","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016032","name":"Dutch Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcf.2026.06.002","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:30:18Z","timestamp":1781609418000},"page":"786-795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A functional comparison of vanzacaftor\/tezacaftor\/deutivacaftor and elexacaftor\/tezacaftor\/ivacaftor in patient-derived intestinal organoids with rare CFTR variants"],"prefix":"10.1016","volume":"25","author":[{"given":"Suzanne","family":"Kroes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4959-4535","authenticated-orcid":false,"given":"Lara","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleen N.","family":"Sonneveld-van Kooten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne","family":"Winkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2959-9964","authenticated-orcid":false,"given":"Kris","family":"De Boeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0828-8630","authenticated-orcid":false,"given":"Margarida","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis K","family":"van der Ent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Beekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Spelier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2026.06.002_bib0001","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.jcf.2026.06.002_bib0002","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2026.06.002_bib0003","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/14728214.2017.1418324","article-title":"An update on new and emerging therapies for cystic fibrosis","volume":"22","author":"Hudock","year":"2017","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.jcf.2026.06.002_bib0004","doi-asserted-by":"crossref","first-page":"a009761","DOI":"10.1101\/cshperspect.a009761","article-title":"Cystic fibrosis transmembrane regulator correctors and potentiators","volume":"3","author":"Rowe","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jcf.2026.06.002_bib0005","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.chembiol.2014.02.021","article-title":"VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface","volume":"21","author":"Eckford","year":"2014","journal-title":"Chem Biol"},{"key":"10.1016\/j.jcf.2026.06.002_bib0006","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jcf.2021.03.011","article-title":"Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR","volume":"20","author":"Veit","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.002_bib0007","article-title":"Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment","volume":"11","author":"Shaughnessy","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2026.06.002_bib0008","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jcf.2011.12.005","article-title":"Ivacaftor potentiation of multiple CFTR channels with gating mutations","volume":"11","author":"Yu","year":"2012","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.002_bib0009","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jcf.2026.06.002_bib0010","year":"2026","journal-title":"Kaftrio"},{"key":"10.1016\/j.jcf.2026.06.002_bib0011","unstructured":"U.S. Food & Drug Administration. Highlights of prescribing information. Preprint at (2019)."},{"key":"10.1016\/j.jcf.2026.06.002_bib0012","unstructured":"Vertex Pharmaceuticals. Vertex announces U.S. FDA approval for TRIKAFTA (elexacaftor\/tezacaftor\/ivacaftor and ivacaftor) to include additional nson-F508del TRIKAFTA-responsive variants. (2024)."},{"key":"10.1016\/j.jcf.2026.06.002_bib0013","article-title":"The French compassionate programme of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","volume":"61","author":"Burgel","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.06.002_bib0014","unstructured":"European Medicines Agency. Combination of cystic fibrosis medicines to treat patients with rare mutations. https:\/\/www.ema.europa.eu\/en\/news\/combination-cystic-fibrosis-medicines-treat-patients-rare-mutations (2025)."},{"key":"10.1016\/j.jcf.2026.06.002_bib0015","unstructured":"European Vertex. European Commission approves expanded label for KAFTRIO\u00ae in combination with Ivacaftor for people with Cystic Fibrosis https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/european-commission-approves-expanded-label-kaftrior-combination; 2025."},{"key":"10.1016\/j.jcf.2026.06.002_bib0016","unstructured":"Vertex. Vertex announces US FDA approval of ALYFTREK\u2122, a once-daily next-in-class CFTR modulator for the treatment of cystic fibrosis. https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/vertex-announces-us-fda-approval-alyftrektm-once-daily-next (2024)."},{"key":"10.1016\/j.jcf.2026.06.002_bib0017","unstructured":"Vertex. Vertex announces European Commission approval of ALYFTREK\u00ae, a new once-daily CFTR modulator for the treatment of cystic fibrosis. https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/vertex-announces-european-commission-approval-alyftrekr-new-once (2025)."},{"key":"10.1016\/j.jcf.2026.06.002_bib0018","unstructured":"clinicaltrials.gov. A phase 3 study of VX-121 combination therapy in participants with cystic fibrosis (CF) heterozygous for F508del and a minimal function mutation (F\/MF). https:\/\/clinicaltrials.gov\/study\/NCT05033080?tab=results (2024)."},{"key":"10.1016\/j.jcf.2026.06.002_bib0019","unstructured":"Vertex. 971 people age 12 years and older participated across 2 studies comparing ALYFTREK\u00ae to TRIKAFTA\u00ae (elexacaftor\/tezacaftor\/ivacaftor and ivacaftor) https:\/\/www.alyftrek.com\/study-results\/trials-1-and-2; 2026."},{"key":"10.1016\/j.jcf.2026.06.002_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103655","article-title":"Comparative efficacy and safety of CFTR modulators for people with cystic fibrosis with phe508del mutation: a systematic review and Bayesian network meta-analysis","volume":"90","author":"Safeer","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jcf.2026.06.002_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.27487","article-title":"C-reactive protein changes in adult and pediatric people with cystic fibrosis during treatment of pulmonary exacerbations","volume":"60","author":"Zuckerman","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.06.002_bib0022","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ng.2745","article-title":"Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene","volume":"45","author":"Sosnay","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jcf.2026.06.002_bib0023","doi-asserted-by":"crossref","first-page":"344ra84","DOI":"10.1126\/scitranslmed.aad8278","article-title":"Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis","volume":"8","author":"Dekkers","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcf.2026.06.002_bib0024","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm.3201","article-title":"A functional CFTR assay using primary cystic fibrosis intestinal organoids","volume":"19","author":"Dekkers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jcf.2026.06.002_bib0025","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00508-2021","article-title":"Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression","volume":"60","author":"Muilwijk","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.06.002_bib0026","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jcf.2020.11.007","article-title":"Lumacaftor\/ivacaftor in people with cystic fibrosis with an A455E\u2013CFTR mutation","volume":"20","author":"Berkers","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.002_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2020.100019","article-title":"Protocol for application, standardization and validation of the forskolin-induced swelling assay in cystic fibrosis Human colon organoids","volume":"1","author":"Vonk","year":"2020","journal-title":"STAR Protoc"},{"key":"10.1016\/j.jcf.2026.06.002_bib0028","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914539","article-title":"CFTR function restoration upon Elexacaftor\/Tezacaftor\/ivacaftor treatment in patient-derived intestinal organoids with rare CFTR genotypes","volume":"24","author":"Lefferts","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2026.06.002_bib0029","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1021\/acschembio.3c00310","article-title":"CFTR folding: from structure and proteostasis to cystic fibrosis personalized medicine","volume":"18","author":"McDonald","year":"2023","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.jcf.2026.06.002_bib0030","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jcf.2023.03.004","article-title":"FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes","volume":"22","author":"de Poel","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.002_bib0031","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.chembiol.2023.05.001","article-title":"General trends in the effects of VX-661 and VX-445 on the plasma membrane expression of clinical CFTR variants","volume":"30","author":"McKee","year":"2023","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.jcf.2026.06.002_bib0032","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcf.2026.06.002_bib0033","unstructured":"BenchChem Technical Support Team. Unraveling the Molecular interface: a technical guide to the (R)-vanzacaftor binding site on F508del-CFTR. https:\/\/pdf.benchchem.com\/12380\/Unraveling_the_Molecular_Interface_A_Technical_Guide_to_the_R_Vanzacaftor_Binding_Site_on_F508del_CFTR.pdf (2025)."},{"key":"10.1016\/j.jcf.2026.06.002_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102542","article-title":"Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator","volume":"24","author":"Laselva","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.jcf.2026.06.002_bib0035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/jpet.117.241497","article-title":"Altering metabolic profiles of drugs by precision deuteration 2: discovery of a deuterated analog of ivacaftor with differentiated pharmacokinetics for clinical development","volume":"362","author":"Harbeson","year":"2017","journal-title":"J Pharmacol Exp Therap"},{"key":"10.1016\/j.jcf.2026.06.002_bib0036","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1085\/jgp.200609667","article-title":"G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR, exhibit distinct gating defects","volume":"129","author":"Bompadre","year":"2007","journal-title":"J Gener Physiol"},{"key":"10.1016\/j.jcf.2026.06.002_bib0037","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1513\/AnnalsATS.201609-689OC","article-title":"Lumacaftor\/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTR","volume":"14","author":"Rowe","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2026.06.002_bib0038","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jcf.2024.09.019","article-title":"Elexacaftor\/tezacaftor\/ivacaftor efficacy in intestinal organoids with rare CFTR variants in comparison to CFTR-F508del and CFTR-wild type controls","volume":"24","author":"Kroes","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.002_bib0039","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1038\/s41467-020-18101-8","article-title":"CFTR trafficking mutations disrupt cotranslational protein folding by targeting biosynthetic intermediates","volume":"11","author":"Shishido","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcf.2026.06.002_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.921680","article-title":"Pharmacological responses of the G542X-CFTR to CFTR modulators","volume":"9","author":"Fang","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jcf.2026.06.002_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103476","article-title":"Elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis harbouring two CFTR class I variants: real-world data from the French compassionate programme","volume":"88","author":"Burgel","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jcf.2026.06.002_bib0042","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S1569-1993(23)00236-9","article-title":"WS09.02 theratyping molecular defects of CFTR rare variants in patient derived rectal organoids","volume":"22","author":"Soeffers","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.002_bib0043","article-title":"Highlights of prescribing information -","year":"2025","journal-title":"Alyftrek"},{"key":"10.1016\/j.jcf.2026.06.002_bib0044","article-title":"Highlights of prescribing information -","year":"2021","journal-title":"Trikafta"},{"key":"10.1016\/j.jcf.2026.06.002_bib0045","unstructured":"Cystic Fibrosis Foundation. CFTR modulator therapies. 2026."},{"key":"10.1016\/j.jcf.2026.06.002_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1661417","article-title":"Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR","volume":"16","author":"Pranke","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2026.06.002_bib0047","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S2213-2600(24)00205-4","article-title":"Evaluation of elexacaftor\u2013tezacaftor\u2013ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial","volume":"12","author":"Solomon","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2026.06.002_bib0048","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00770-2023","article-title":"Organoid-guided synergistic treatment of minimal function CFTR mutations with CFTR modulators, roflumilast and simvastatin: a personalized approach","volume":"63","author":"Spelier","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.06.002_bib0049","doi-asserted-by":"crossref","first-page":"C628","DOI":"10.1152\/ajpcell.00908.2025","article-title":"Have we been overlooking K channels in the era of CFTR modulators?","volume":"330","author":"Becq","year":"2026","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jcf.2026.06.002_bib0050","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176328","article-title":"Potentiation of BKCa channels by cystic fibrosis transmembrane conductance regulator correctors VX-445 and VX-121","volume":"134","author":"Kolski-Andreaco","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2026.06.002_bib0051","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0060-2024","article-title":"Medication adherence to CFTR modulators in patients with cystic fibrosis: a systematic review","volume":"33","author":"Hansen","year":"2024","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jcf.2026.06.002_bib0052","unstructured":"BioSpace. Cystic fibrosis option but stock still down. https:\/\/www.biospace.com\/fda\/vertex-wins-fda-approval-for-new-cystic-fibrosis-option-but-stock-still-down#:~:text=Vertex%20has%20established%20a%20list%20price%20of%20around%20%24370%2C000%20for%20Alyftrek. (2024)."},{"key":"10.1016\/j.jcf.2026.06.002_bib0053","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jcf.2022.04.007","article-title":"Current prices versus minimum costs of production for CFTR modulators","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.002_bib0054","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.002_bib0055","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jcf.2025.10.007","article-title":"Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor","volume":"24","author":"Burgel","year":"2025","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:07:45Z","timestamp":1790107665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326016437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1569199326016437"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.06.002","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A functional comparison of vanzacaftor\/tezacaftor\/deutivacaftor and elexacaftor\/tezacaftor\/ivacaftor in patient-derived intestinal organoids with rare CFTR variants","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}